"Pharmaceutical Express" CDE issued a paper to accelerate the new crown vaccine on the market a number of drugs will soon be approved.

August 17, 2020 / Pharmaceutical Information At a Glance: Sanofi's $3.68 billion acquisition of Principia; FDA approves Roche's innovative IL-6 inhibitor listing to treat optic neurospinal cord genealogy disorder; JW (Cayman) Therapeutics filed for an IPO on the Hong Kong Stock Exchange; And Goly announces: ASC22II.a clinical trial completes the first treatment of hepatitis B patients... Daily fresh medicine news, speed reading society and you pay attention to! Part 1 Policy Brief August 16 New confirmed cases 22 cases are overseas imported cases August 16 0-24 hours, 31 provinces (autonomous regions, municipalities directly under the Central Government) and Xinjiang Production and Construction Corps reported 22 new confirmed cases, all overseas import cases (Guangdong 8 cases, Yunnan 4 cases, Shanghai 3 cases, Shaanxi 3 cases, Sichuan 2 cases, Fujian 1 case, Shandong 1 case);
(National Health And Wellness Commission) CDE to promote the new crown vaccine market process, CDE released the "new coronavirus prevention vaccine research and development technical guidelines (trial)" and other 5 documents, including "new coronavirus prevention vaccine clinical evaluation guidelines (trial)" from the clinical needs, safety, effectiveness, listing evaluation, overseas clinical trial data and other aspects of the new crown vaccine market evaluation standards.
guidelines for the development of new crown vaccines, aimed at ensuring quality and accelerating the launch of new crown vaccines.
(CDE) subsidy of 100,000 basic doctors who understand this technology recently, Gansu Provincial Health and Health Commission issued "on the issuance of the 2020 Chinese medicine heritage and development project implementation plan notice", proposed in the three districts and three deep poverty-stricken areas of township health hospitals and community health service centers to carry out comprehensive chinese medicine service area (Chinese medicine hall) service capacity-building, the central government in accordance with the standard of 100,000 yuan / subvented.
(Gansu Provincial Health Commission) Part 2 After observing that the EU's first pre-order agreement for a new crown vaccine cost AstraZeneta, the European Commission (EC) and AstraZeneta reached an agreement that ecclesiastia may choose to purchase an further 100 million doses of vaccine on behalf of EU member states once the latter's potential vaccine for COVID-19, AZD1222, is proven to be safe and effective.
.Sanofi's $3.68 billion acquisition of Principia Sanofi and Principia resulted in a total of about $3.68 billion.
through this acquisition, Sanofi acquired three Bruton tyrosine kinase (BTK) inhibitors under study by Principia, and Principia's BTK inhibitors will increase Sanofi's efforts to accelerate and build a portfolio of next-generation immunologic disease-changing therapeutic drugs.
(Now) JW (Cayman) Therapeutics filed an IPO application with the Hong Kong Stock Exchange on August 14th, and the co-sponsors are Goldman Sachs and UBS.
JW Cayman, who is committed to the development of cell therapies, submitted its new application for the third-line treatment of diffuse large B-cell lymphoma at Chinese mainland in June.
(Pharmaceutical Mission) A-round financing to promote the development of new drugs in the field of severe bone and muscle disease 16, Anziz sheng announced that the company recently completed tens of millions of U.S. dollars A-round financing.
This round of financing by Gao Wei Ventures, Aobo Asia and Guangzhou Yuanxuan origin investment, the last round of investment institutions Guangzhou Junshi, Taifu Capital, Chung Yu investment to give continued support.
funding will be used to accelerate the development of the company's clinical phase and preclinical innovations in the field of severe osteoarthrular muscle disease.
(Angie's Announcement) Part 3 Drug News Goliath announced: ASC22II.a clinical trial completed the first case of hepatitis B patients drug treatment Goliath announced today: ASC22II.a clinical trial completed the first case of hepatitis B patients.
ASC22 is the world's first pD-L1 antibody to be injected under the skin.
(XINHUA) -- The FDA has approved Roche's innovative IL-6 inhibitor for the treatment of optic neurospinalitis spectrum disorder, roche-owned Genente announced that the U.S. FDA has approved Enspryng's listing to treat adult patients with AQP4 antibody-positive optic neurospinal cord genealogy disorder (NMOSD).
Enspryng is the only single anti-drug approved for the treatment of NMOSD, and the IL-6 signaling pathline plays a key role in the associated inflammation caused by NMOSD.
(Drug Mingkangde) today 5 new drugs approved clinically from Johnson and Johnson, Anjin / Baiji Shenzhou, Junshi biological ... CDE's latest announcement, a number of new drugs have been approved by clinical trials, including Amgen and Baiji Shenzhou jointly declared BCMA dual resistance, Johnson and Johnson's Janssen Pharmaceuticals developed anti-NKG2D monoclonal antibody, Regen bioPD-1 antibody Ripley monoanti, as well as Shenzhou cell VEGF monoantigen and PD-1 monoantigen and so on.
(CDE) Bayer "Chlorinated Radon 223Ra Injection" will be approved in China recently, Bayer in China submitted the application for the listing of chlorinated radon 223Ra injection into the "in-approval" stage, is expected to be approved in the near future, the treatment of prostate cancer bone metastasis.
(Medical Rubik's Cube) Cenegermin eye drops were approved in China, Cenegermin eye drops were approved for listing in China to treat neurotrophic corneitis.
the drug, developed by Dompé Pharmaceuticals, is one of the first clinically urgent overseas drugs.
(Pharmaceutical Rubik's Cube) East Sunshine 3 diabetes compound preparations will be approved recently, Dongshuangon 3 new Class 4 diabetes products (Liglitatin metformin tablets, phosphate segritin tablets and Sigretin metformin tablets) listing applications into the "in the approval" stage, is expected to be formally approved recently.
(Pharmaceutical Rubik's Cube) Colum Pharmaceuticals injection with yew alcohol (albumin binding type) is about to be approved by Colum Pharmaceuticals submitted 4 classes of generic drug injection yew alcohol (albumin binding type) listing application into the administrative approval stage, is expected to be formally approved in the near future.
albumin yew alcohol, developed by Abraxis, is a new preparation that combines yew alcohol with albumin, overcomes the shortcomings of poor water solubility, low efficiency and side effects of ordinary yew alcohol, and was approved by the FDA in January 2005 to treat breast cancer, and was subsequently approved for the treatment of lung and pancreatic cancer.
(Pharmaceutical Rubik's Cube) Fosun Pharmaceutical amitriline tablets through the consistent evaluation of the 16th, Fosun Pharma announced that the controlling subsidiary Hunan Dongting Pharmaceutical Industry received the State Drug Administration issued on the hydrochloric acid amitriline tablets "Drug Supplemental Application Approval Notice", the drug through generic drug quality and efficacy consistency evaluation, the company for the product's first evaluation enterprise.
(Fosun Pharma Announcement) Hesco acetic acid capofen net access to the "drug registration certificate" Hesco issued a notice that the wholly-owned subsidiary Liaoning Haisco recently received the National Drug Administration issued by the injection acetate capofen net "drug registration certificate."
acetic acid capofen net is the first new antifungal drug of echiatoxin.
has the characteristics of wide antibacterial spectrum, long half-life, high binding rate with human serum protein, fewer adverse reactions and good patient tolerance, and is a clinically urgently needed anti-deep fungal infection drug.
(Haysco announcement) tablets 1 class of new drug declaration eager to seize the hepatitis chemical drug market days ago, chipissued a notice that class 1 new drug PZH2109 capsule declaration clinically obtained CDE acceptance, the drug is mainly used to treat non-alcoholic fatty hepatitis, the United States and China do not have the same target of the same adaptive drug was approved for market.
(Filmannouncement)